The Compound Eye – Vaccine’s Day Out

Guidelines for Evaluation of Nano-Agri Input and Nano-Agri Products! 

The Department of Biotechnology invites comments on ‘Guidelines for Evaluation of Nano-Agri Input and Nano-Agri Products in India” from all the stakeholders- government agencies, institutions, industry/researchers engaged in research & development in Nanobiotechnology. It is requested that comments/observations pertaining to the same may be conveyed positively by 31st August, 2019 to Dr. Suchita Ninawe, Adviser, DBT only through email at policy[at]dbt[dot]nic[dot]in

Hundreds of nano-agriinproducts (NAIPs) and nano-agriproducts (NAPs) using nanotechnology are already on the market even though there are no specific policies regulations for their control. Therefore, there is a need to develop the policy and regulations in place. (Read more)

Fighting Ebola.. Continued

In a previous edition, The Compound Eye covered the on-going Ebola outbreak in the Democratic Republic of Congo. The chief challenge in curbing the outbreak has been mistrust in the healthcare system, including misinformation spread about the Ebola vaccine.

However, in a new turn of events, two drug candidates have shown promising results against Ebola. Preliminary results, of 499 of the participants, show that two of the candidates, REGN-EB3 and mAb114, were highly effective in treating people infected with the virus. (Read more)

Vaccines in India: 

The Indian Council of Medical Research (ICMR) has launched India’s first large-scale trial for two new TB vaccines. This is the first time a large preventive TB vaccine trial involving more than 12,000 healthy household contacts of newly diagnosed TB patients from across six states of India are set to be enrolled.

For these trials, the six states including Delhi, Maharashtra, Odisha, Telangana and Karnataka, with two thousand participants from each state are to be enrolled over the next seven to eight months. Further, seven main centres will have six sub-sites, where these trials will be conducted. (Read more)

Meanwhile, in some non-vaccine news:

A vaccine for Chlamydia: Ha! There is no escaping vaccine news this fortnight. The first vaccine against chlamydia has passed its first test in humans.Chlamydia, caused by the bacterium Chlamydia trachomatis, is one of the most common sexually transmitted diseases, with around 131 million women and men newly infected worldwide each year. (Read more)